InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.
Previously mechanistic model predicting concentration of monoclonal antibodies (mAbs) and target occupancy in cerebrospinal fluid was developed by InSysBio in collaboration with discoveric bio alpha. The further project expansion aims to use the model to support first-in-human study of NIDB-3101 leveraging cyno-to-human translation and available published clinical data as benchmarks.
Jean-Philippe Courade, CSO of discoveric bio alpha, comments on the project extension, “We were inspired to experience InSysBio’s cutting-edge mechanistic modeling approach during our first collaboration. Now we are excited to continue the project that will provide us with a range of new predictions to efficiently advance through the next stages of our antibody development”.
Oleg Demin Jr, Scientific Director, InSysBio, highlights, “We are encouraged by the opportunity to implement our expertise and solutions to further unleash the potential of the model. With its help we will support the selection of the starting dose and pharmacologically active dose to optimize first-in-human study”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
About discoveric bio alpha
discoveric bio alpha is a privately owned company part of a group of three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. It is located in Pfäffikon, Switzerland. For more information, visit https://www.discovericbio.com/
| ← | July 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
1.
06 Jul 2020 17:37
InSysBio to announce the launch of its new tool Heta compiler
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
1.
27 Jul 2020 11:45
InSysBio to evolve its Open Source QSP model of COVID-19
InSysBio has presented a new portion of results in the framework of development of COVID-19 QSP model.
2.
27 Jul 2020 16:42
InSysBio to present its posters at AAIC 2020 Virtual Event
InSysBio announces its participation in AAIC 2020 Virtual Event. Alzheimer's Association International Conference is held virtually on July 27-31. InSysBio team presents two posters within its frames
|
28
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
